<div id="readability-page-1"><p>Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the twelve research firms that are presently  covering the stock, Marketbeat reports. One investment analyst  has rated the stock with a sell rating, ten have given a buy rating and one  has given a strong buy rating to  the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $33.1111.</p><ul><li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li></ul><p>A number of equities analysts have commented on CNTA shares. Guggenheim  reissued a &#34;buy&#34; rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Truist Financial  set a $30.00 price target on Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen upgraded Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 27th. Stephens began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an &#34;overweight&#34; rating and a $35.00 target price for the company. Finally, Chardan Capital  reissued a &#34;buy&#34; rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th.</p><p><b>Read Our Latest Stock Analysis on Centessa Pharmaceuticals</b></p><h2>Insider Transactions at Centessa Pharmaceuticals</h2><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the completion of the sale, the insider directly owned 197,394 shares in the company, valued at $4,224,231.60. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares of the company's stock, valued at approximately $3,159,078. This represents a 24.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,964 shares of company stock worth $4,106,481 in the last ninety days. Insiders own  7.09% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in  Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the period.  Osterweis Capital Management Inc. purchased a new stake in shares of  Centessa Pharmaceuticals during the 1st quarter valued at approximately $47,000.  Bank of New York Mellon Corp acquired a new position in  Centessa Pharmaceuticals in the first quarter valued at approximately $147,000.  Fox Run Management L.L.C. purchased a new position in  Centessa Pharmaceuticals in the first quarter worth approximately $160,000.  Finally, Vestal Point Capital LP acquired a new stake in  Centessa Pharmaceuticals during the first quarter worth $214,000. Institutional investors and hedge funds own  82.01% of the company's stock. </p><h2>Centessa Pharmaceuticals Stock Down 1.1%</h2><p>Shares of NASDAQ CNTA opened at $27.32 on Tuesday. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -14.93 and a beta of 1.56. The company's 50-day simple moving average is $23.36 and its 200-day simple moving average is $17.65. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $29.29. </p><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02).  Equities analysts predict that  Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year. </p><h2>Centessa Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Centessa Pharmaceuticals</li><li>Market Cap Calculator: How to Calculate Market Cap</li><li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li><li>What is the Nikkei 225 index?    </li><li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li><li>3 Warren Buffett Stocks to Buy Now</li><li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTA

<p>Centessa Pharmaceuticals PLC (NASDAQ:CNTA) has received a consensus rating of "Moderate Buy" from twelve research firms. Analysts have set an average 12-month target price of $33.11. Recent insider transactions include sales by Mario Alberto Accardi and CTO Tia L. Bush. Institutional investors own 82.01% of the company's stock. Centessa Pharmaceuticals reported a quarterly loss of $0.41 per share, missing estimates by $0.02.</p>

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of "Moderate Buy" from Analysts